Simonetta Mocci

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse

Marco Cecchini, Melissa G. Dominguez, Simonetta Mocci et al. · Development · 1994 · 565 citations

Life Sciences, Cell Biology, Immunology +13

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Solange Peters, Scott Gettinger, Melissa L. Johnson et al. · Journal of Clinical Oncology · 2017 · 419 citations · Full text

Medicine, Oncology, Pharmacology +17

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne et al. · Journal of Clinical Oncology · 2017 · 326 citations

Medicine, Oncology, Pharmacology +13

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Marcin Kowanetz, Wei Zou, Scott Gettinger et al. · Proceedings of the National Academy of Sciences · 2018 · 239 citations · Full text

Medicine, Immunology, Pharmacology +17